vaccination-1215279_960_720

IGT Biologika’s COVID-19 vaccine becomes third in Germany to be approved for human trials

pharmafile | October 2, 2020 | News story | Medical Communications, Research and Development COVID-19, IDT Biologika, Vaccine 

German biotech IDT Biologika has become the third company in the country to secure approval from the nation’s vaccine regulator to progress into human trials of its prophylactic therapy for the prevention of COVID-19 infection, it has emerged.

IDT Biologika’s candidate is currently being developed in partnership with the German Centre for Infection Research (DZIF), and follows in the steps of vaccine therapies from other German firms BioNTech and CureVac, which both secured approval for human testing earlier this year.

In the first planned study, the vaccine will be tested in 30 participants between the ages of 18 and 55, administered in two doses every four weeks.

Should the first study prove successful, the company plans to push the therapy into Phase 2 trials in older patients before the end of the year.

Advertisement

Klaus Cichutek, Head of the Paul Ehrlich Institut, the Federal Institute for Vaccines and Biomedicines and part of the German Federal Ministry of Health explained: “If data from Phase 3 trials shows the vaccines are effective and safe, the first vaccines could be approved at the beginning of the year, possibly with conditions attached…Based on assurances from manufacturers, the first doses for people in Germany will be available at that time, in accordance with the priorities set by the Standing Committee on Vaccination.”

IDT Biologika is currently involved in the development of six different COVID-19 vaccine projects.

Matt Fellows

Related Content

drug-trials

BioNet receives positive EMA opinion on new pertussis vaccine

BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …

Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON

Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …

covid_cell

COVID-19 vaccine eligibility creates challenges for UK pharmacies

Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …

The Gateway to Local Adoption Series

Latest content